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inﬂammatory effects of trilostane.
Objective: The aim of this study was to elucidate the novel pharmacologic activity of trilostane in a series
of inﬂammation and nociception signal-ﬁnding models.
Methods: Anti-inﬂammatory effects of trilostane were evaluated in lipopolysaccharide-induced systemic
and lung inﬂammation models and in a 2,4-dinitroﬂuorobenzene–induced delayed-type hypersensitivity
(DTH) model in the mouse ear. The analgesic activities of trilostane were evaluated in a hot plate
nociception model as a function of paw-withdrawal latency and in the formalin-induced nociception
model with a behavioral end point. In all studies, trilostane was administered 15 minutes before challenge.
In the DTH model, the animals were given a second dose 24 hours after the ﬁrst dose.
Results: Trilostane inhibited tumor necrosis factor-α and monocyte chemoattractant protein-1 production
in the lipopolysaccharide-induced systemic and pulmonary inﬂammation models. It also signiﬁcantly
reduced ear swelling in the 2,4-dinitroﬂuorobenzene–induced DTH model. In the hot plate nociception
model, trilostane increased the latency of paw-licking behavior. Trilostane also signiﬁcantly reduced the
duration of pain behaviors in the late phase of the formalin-induced inﬂammatory pain model.
Conclusions: These signal-ﬁnding studies suggest that trilostane has novel anti-inﬂammatory and analgesic
properties.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The drug discovery process is a ﬁnancially intensive and time-
consuming process with a high failure rate.1 Many of the failures are
due to safety issues that arise in Phase I human studies. One novel
approach to lessen this risk is by “repurposing” existing US Food and
Drug Administration (FDA)-approved drugs for alternative indica-
tions.2,3 These drugs have well-documented safety proﬁles in
humans, which can potentially speed up the drug discovery process
and mitigate risks.4 It has long been recognized that many existing
drugs have off-target effects, which may be beneﬁcial for secondary
indications that the drug was not originally intended to target.r Inc.
Med Valley Discoveries, 4520
ng).
Open access under CC BY-NC-ND liceHowever, these additional activities are often not well characterized.
These considerations have led to efforts to repurpose existing drugs
for novel indications. A number of investigators have screened
panels of existing drugs against alternative indications and have
identiﬁed new indications for these drugs.5
Although there are a number of anti-inﬂammatory drugs
available in the United States that target a variety of pathways,
there is still an unmet market for new drugs that have fewer
adverse effects and are more efﬁcacious.6 In an effort to identify
new anti-inﬂammatory agents, we screened a library of FDA-
approved compounds in several mouse models of inﬂammation.
Trilostane, an inhibitor of 3 β-hydroxysteroid dehydrogenase, was
found to inhibit tumor necrosis factor-α (TNF-α) production
in a systemic lipopolysaccharide (LPS) challenge model during
our screening process. We then conﬁrmed this signal in a pulmonary
LPS challenge model and a delayed-type hypersensitivity model
induced by 2,4-dinitroﬂuorobenzene (DNFB). Because pain is a
frequent component in inﬂammatory disease, we further evaluated
trilostane in a thermal nociceptive pain model and an inﬂammatory
pain model. Our observations are summarized in this brief report.nse.
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The anti-inﬂammatory effects of trilostane were studied in 3 ani-
mal models of inﬂammation: systemic and pulmonary LPS-induced
inﬂammation models and a DNFB-induced delayed-type hyper-
sensitivity model. The analgesic properties of trilostane were
studied in the hot plate nociception model and the formalin-
induced inﬂammatory pain model. All in vivo protocols were
approved by the Institutional Animal Care and Use Committee of
Melior Discovery, Inc (Exton, Pennsylvania).
Animals
Male CD-1 (ICR) mice (Ace Animals, Boyertown, Pennsylvania)
8 to 10 weeks of age were used in all models. The animals were
housed 6 per cage and kept on a standard 12-hour light cycle. The
mice were provided food and water ad libitum. Six animals were
used in each group.
Drug administration
Trilostane (LKT Laboratories, Inc, St Paul, Minnesota) was
administered intraperitoneally at 30 mg/kg in all studies. This
dose level was based on the highest reported dose of trilostane in
mice that did not have any adverse effect.7 The vehicle was 0.4%
Tween 80 (ICI Americas Inc, Bridgewater, New Jersey) in saline. The
positive controls were dexamethasone 20 mg/kg for all the
inﬂammation models or oxycodone 10 mg/kg for the pain models.
Systemic inﬂammation
LPS (heat-killed Escherichia coli 0127:B5; Sigma-Aldrich Corpo-
ration, St Louis, Missouri) was prepared in phosphate-buffered
saline (PBS) at a concentration of 0.025 mg/mL and injected at
10 mL/kg intraperitoneally for a ﬁnal dose of 0.25 mg/kg.8–11
Trilostane was administered 15 minutes before the LPS challenge.
Dexamethasone was used as a positive control and was adminis-
tered at the same time as the test article. Ninety minutes after the
LPS challenge, blood samples were collected via the retro-orbital
route. Serum was collected, and TNF-α levels were measured by
ELISA (R&D Systems Inc, Minneapolis, Minnesota).
Pulmonary inﬂammation
Mice were prophylactically dosed with trilostane, dexametha-
sone, or vehicle 15 minutes before intranasal challenge with LPS.
For intranasal administration of LPS, the mice were anesthetized
by using an intraperitoneal injection of ketamine/xylazine (8 mg/
1.2 mg in 1 mL of PBS) and suspended vertically while 50 μg of LPS
(in 1 mg/mL) was instilled into the nares in 3 boluses.12,13 Mice
were then held vertically for 5 minutes to allow full penetration
of LPS into the lungs. Four hours after the LPS challenge, the mice
were killed by carbon dioxide exposure, and the lungs were
collected and homogenized in 1 mL of magnesium and calcium-
free PBS containing a protease inhibitor cocktail (Sigma-Aldrich
Corporation, #P8340). Homogenates were centrifuged at 3000 rpm
for 10 minutes, and the supernatant was analyzed for levels of
monocyte chemoattractant protein-1 (MCP-1) by ELISA (Thermo
Fisher Scientiﬁc Inc, Rockford, Illinois).
Delayed-type hypersensitivity
Mice were anesthetized by an intraperitoneal injection of
ketamine/xylazine (8 mg/1.2 mg in 1 mL of PBS). Their backs were
shaved and sensitized with 0.5% DNFB (in 4:1 acetone/olive oil)
twice over 2 consecutive days.14,15 Five days after sensitization,0.2% DNFB was applied with a brush to the dorsal surface of the right
ear, while the left ear was painted with acetone as a control. Ear
thickness at 3 separate locations was measured before challenge and
then at 24 and 48 hours after challenge. Trilostane was administered
15 minutes before challenge and 24 hours after the ﬁrst dose.
Hot plate analgesia
Mice were treated with trilostane, oxycodone, or vehicle 15
minutes before exposure to the hot plate. The animals were
individually placed on a preheated 521C hot plate (Columbus
Instruments, Columbus, Ohio). An open-ended cylindrical plexi-
glass tube with a diameter of 30 cm was placed on top of the hot
plate to prevent the mice from escaping but leaving their paws
exposed to the hot plate.16–18 Time from placing the animals on
the hot plate to the time of the ﬁrst paw lick was measured with
a stopwatch. To prevent tissue damage, the mice were removed
from the hot plate after 1 minute regardless of their response.
Formalin-induced analgesia
Mice were treated with trilostane, oxycodone, or vehicle
15 minutes before formalin injection. A total of 20 mL of 2% formalin
was injected into the left hind paw, nearly parallel to the plantar
surface of the mid-foot. The animals were observed, and the
amount of time spent exhibiting pain behaviors (licking, biting,
shaking, tucking, or favoring the injected paw) was recorded. The
cumulative amount of time spent exhibiting pain behaviors within
each of the six 5-minute increments was analyzed for a total of
30 minutes per mouse.19–22 Data were reported as the cumulated
duration of pain-related behaviors within each time interval.
Data analysis and statistics
All data are presented as mean (SEM), and ANOVA was used to
analyze statistical signiﬁcance. Analysis of the data was performed
by using MS Excel (Microsoft Inc, San Jose, California).Results
LPS-induced systemic inﬂammation
Systemic LPS challenge was used as a ﬁrst-tier model to
conﬁrm the anti-inﬂammatory effects of trilostane, which were
initially identiﬁed in the same model in the screen. The serum
TNF-α level serves as a biomarker to gauge the level of anti-
inﬂammatory efﬁcacy. Intraperitoneal challenge with 0.25 mg/kg
of LPS resulted in an increase of 3049 pg/mL of TNF-α in the serum
by 90 minutes. In the mice that had been pretreated with 30 mg/kg
of trilostane before LPS challenge, the TNF-α level was signiﬁcantly
reduced by 64.3% to 1088 pg/mL (P o 0.05). The response to
trilostane was not as great as that of the positive control (20 mg/kg
of dexamethasone), which resulted in background levels of ciru-
lating TNF-α (Figure 1A).
LPS-induced pulmonary inﬂammation
The pulmonary challenge using LPS via intranasal instillation
served as a model for local inﬂammation. MCP-1 levels in lung
homogenates served as a biomarker to assess the anti-
inﬂammatory effects of trilostane in this model. In the LPS-
challenged animals that were treated with vehicle control, the
levels of MCP-1 in the lung increased from undetectable to 12,077
pg/mL at 4 hours’ postchallenge. This elevation of MCP-1 was
signiﬁcantly reduced by trilostane pretreatment (by 71% to
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Figure 1. (A) Systemic challenge with LPS led to an increase in serum TNF-ɑ level which was signiﬁcantly reduced by trilostane treatment. Dexamethasone treatment
completely inhibited TNF-ɑ up-regulation (nP o 0.05). (B) The animals were given intranasal doses of LPS for pulmonary challenge. At 4 hours post challenge, the lung
homogenate MCP-1 level of the vehicle group reached 12077 pg/ml. Trilostane and dexamethasone treatment signiﬁcantly inhibited this MCP-1 elevation (nP o 0.0001).
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Figure 2. At 5 days post DNFB sensitization, the animals were challenged topically
with DNFB on their right ears. Trilostane signiﬁcantly reduced the resulting ear
swelling at 48 hours post treatment, but the effect was not signiﬁcant at 24 hours.
Dexamethasone treatment completely inhibited the swelling response at all time
points (n P o 0.05).
D. Tung et al. / Current Therapeutic Research 75 (2013) 71–76 733554 pg/mL; P o 0.0001). This level of inhibition is statistically
identical to that provided by the positive control of dexamethasone
20 mg/kg (Figure 1B).
DNFB-induced delayed-type hypersensitivity
The immunomodulatory effects of trilostane were examined in a
contact hypersensitivity model induced by DNFB. The animals were
sensitized to DNFB and then challenged on the right ear 5 days later.
Ear thickness increase was used as an end point. After the initial
sensitization, there was no increase in the ear thickness. On challenge
5 days later, the DNFB-challenged animals that were treated with
vehicle control experienced an increase in ear thickness of 76% to
0.34 mm. The trilostane-treated animals exhibited less swelling, with
a maximum thickness of 0.27 mm at 48 hours. This ﬁnding
constitutes a statistically signiﬁcant 19% reduction (P o 0.05)
compared with the vehicle-treated group. The animals that were
treated with the positive control (dexamethasone) exhibited baseline
levels of swelling (Figure 2). As a measure of the animals’ health,
their weight was measured before and after the dosing period. There
was no decrease in weight, and the weight of the treatment group
was not signiﬁcantly different from the vehicle-treated animals.
Hot plate nociception
The hot plate nociception model was used as a ﬁrst-line signal-
ﬁnding model for evaluating the analgesic potential of testcompounds. In this model, vehicle-treated mice began exhibiting
paw-licking behaviors at 10.8 seconds after exposure to the hot
plate. Trilostane signiﬁcantly delayed the onset of this behavior to
16.5 seconds (P o 0.05). This ﬁnding represents a 34.2% increase in
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Figure 3. (A) Trilostane or oxycodone treatment was administered 15 minutes prior to the hot plate challenge. The vehicle group took an average of 10.5 seconds to react to
the thermal stimulus. Trilostane and oxycodone treatment signiﬁcantly extended the response time to 16.5 seconds and 50.5 seconds, respectively (nP o 0.05). (B) Formalin
injection into the footpad resulted in a pain related licking response which diminished and entered into a secondary phase at 10 minutes post challenge. Trilostane pre-
treatment had no effect on the peak acute phase response, though it did modulate the response slightly towards the end of the acute phase. However, the animals
demonstrated signiﬁcantly reduced response at the 15 and 20 minutes segments during the secondary phase. Oxycodone treatment completely inhibited the acute and
secondary phase response (nP o 0.05).
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exhibited an increased latency of 500% to 50.5 seconds (Figure 3A).
Formalin-induced nociception
Formalin injection into the mouse paw produces a pain-related
irritation that elicites a licking response. The frequency of this
response can be used as a measure of a test compound’s analgesic
property. The response can be divided into an acute phase (phase
I) that lasts for 10 minutes, followed by a late phase (phase II) that
lasts for 30 minutes after the injection. The vehicle-treated
animals exhibited a culmulative licking response of 239.8 seconds
within the ﬁrst 5 minutes. Trilostane pretreatment had no effect
on the peak of the acute phase response; however, between the
5- and 10-minute segment of the acute phase, the cumulative
duration of response was reduced to 121.3 seconds. Although
trilostane decreased this response duration to 46.5 seconds, this
effect was not statistically signiﬁcant. However, in the late phase,trilostane signiﬁcantly decreased the cumulative response (P o
0.05) in the 10- to 15-minute and the 15- to 20-minute time
segments to 53.0 seconds and 74.7 seconds, respectively, com-
pared with 121.3 seconds and 183.2 seconds for the vehicle-treated
group. This outcome constitutes a 62% and a 71% reduction,
respectively. The positive control, oxycodone, completely abol-
ished the licking behavior in phases I and II (Figure 3B).Discussion
Despite intense efforts in the pharmaceutical industry to
discover new treatments for inﬂammatory diseases and pain,
there is still a major unmet need for patients who are refractory
to current therapeutic options or cannot tolerate the substantial
adverse effects.6 One potential source of new therapeutic agents
is the existing pharmacopeia. Most existing drugs have off-target
activities or the intended target is present in additional organs,
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several examples of such repurposing successes. For example,
sildenaﬁl was identiﬁed as a treatment for erectile dysfunction
despite its lack of efﬁcacy for angina.23 In recent years, several
groups have sought to identify and characterize the off-target
activities of existing drugs by screening libraries of these com-
pounds in their models of interest. These programs have resulted
in the approval of miltefosine for the treatment of visceral
leishmaniasis,24 ceftriaxone as a potential treatment for amyotro-
phic lateral sclerosis,25 and astemizole as an antimalarial agent.26
We sought to identify potential new treatments for inﬂamma-
tory diseases and their associated pain by screening our library
of FDA-approved drugs by using several animal models of inﬂam-
mation. The anti-inﬂammatory activity of trilostane was ﬁrst
identiﬁed in an LPS-induced systemic inﬂammation model, in
which trilostane signiﬁcantly inhibited serum TNF-α levels post–
LPS challenge. TNF-α is 1 of the key mediators involved in
inﬂammatory diseases. This homotrimeric cytokine is ﬁrst synthe-
sized as a membrane-bound protein, then cleaved by proteases to
release the soluble cytokine. It is produced by all inﬂammatory
cells and by many noninﬂammatory cells.27 Two key membrane-
bounded TNF receptors can be cleaved into soluble forms: TNFR1
and TNFR2. TNFR1, expressed on almost all nucleated cells,
preferentially binds soluble TNF-α, even though it is activated by
both the soluble and membrane-bound TNF-α.28 The expression of
TNFR2 is mostly restricted to endothelial cells and some immune
cells, such as T cells, B cells, monocytes, and natural killer cells.27,29
TNFR2 can only be fully activated by membrane TNF-α and not by
soluble TNF-α, even though it can bind both forms.30,31 The
concentration of soluble receptors can mediate TNF-dependent
biologic effects by scavenging soluble TNF-α. Due to the high
binding afﬁnity of the soluble form of TNFR2 to TNF-α, it can
decrease TNF-mediated activities by scavenging the cytokine that
can potentially interact with TNFR1.32 Therefore, a decrease in
serum TNF-α levels as observed in the present study is potentially
due to inhibition of TNF-α release or the scavenger effect of the
soluble receptors.
This observation in the systemic LPS challenge study led to a
series of subsequent signal-ﬁnding studies to elucidate its full
anti-inﬂammatory potential. The anti-inﬂammatory effects of
trilostane were further conﬁrmed in a tissue-speciﬁc LPS-
induced pulmonary inﬂammation model using MCP-1 as a
biomarker. The MCP-1 level in lung tissue was signiﬁcantly
attenuated by trilostane treatment. To further expand the under-
standing of trilostane’s anti-inﬂammatory activity, we also tested
the agent in a delayed-type hypersensitivity model, in which we
found that DNFB-induced ear swelling was signiﬁcantly reduced
by trilostane.
Because pain is often a co-factor in inﬂammatory diseases, and
there is a large unmet medical need for novel pain medications,
our goal was to determine if trilostane has any analgesic effects.
Unfortunately, the inﬂammation models used in this set of studies
do not have a strong pain component; therefore, we explored the
analgesic effects of trilostane in several nociception models. We
found that trilostane treatment produced a signiﬁcant increase in
latency of the response to thermal stimulus from a hot plate.
However, the response was relatively small compared with that
generated by oxycodone. Similarly, in the formalin-induced noci-
ception model, trilostane treatment resulted in a signiﬁcant
reduction in pain response behaviors; oxycodone completely
attenuated any pain-related behavioral response in the animals,
however.
Although trilostane treatment did have a signiﬁcant effect on
this pain response during certain time segments in the late phase
of the model, the magnitude of the response was not as potent as
that of oxycodone, and it failed to affect the magnitude of theacute phase response. The dose level for trilostane was selected
based on the highest dose published for mice in the literature that
did not have adverse effects.7 Because oxycodone is the standard
of care for many pain indications, the comparatively mild effects
of trilostane suggest that it would not be competitive as an
analgesic agent.
One question that arises from these observations is whether
the analgesic effect of trilostane on the formalin-induced pain
behavior was due to its anti-inﬂammatory properties or whether
it was a purely analgesic effect. The best evidence for anti-
inﬂammatory–independent analgesic effects of trilostane can be
seen in the hot plate–induced nociception model. The onset of the
paw-withdrawal response was rapid, and there is no inﬂammatory
component in this short-acting model; however, trilostane was
able to affect paw-withdrawal latency. Formalin is a strong irritant
and is capable of inducing a potent pain response that results from
a combination of nociceptive and subsequent inﬂammatory effects.
Although dissecting out which portion of this response was
inhibited by trilostane would be challenging, understanding
the mechanism in play at each stage of the model might shed
some light on trilostane’s mechanism of action. Phase 1 of the
model involves the direct activation of nociceptors.33 The second
phase is sensitive to NSAIDS, mild analgesics, prostaglandin syn-
thesis inhibitors,34 and anti-inﬂammatory steroids (hydrocorti-
sone, dexamethasone), as well as some centrally active drugs
such as gabapentin.20 A number of targets have been implicated
in late-phase formalin inﬂammatory pain models. These include
casein kinase 2, nitric oxide, nitric oxide synthase, arachidonic
acid, cytokines, TNF-α, activation of p38 MAPK, and MAP kinase
kinase 3.35,36 It is difﬁcult to tell which of these targets, or
which combination of them, plays a part in the analgesic effect
of trilostane without detailed in vitro analyses, which is beyond
the scope of this brief report. The attenuation of the pain behaviors
observed in the late stage of this model was probably due to a
combination of the anti-inﬂammatory effect and the analgesic
effects of trilostane. One good alternative approach would be to
demonstrate the analgesic effects of trilostane in a purely noci-
ceptive model without an inﬂammatory component (ie, the
hot plate model) as described in this article. We also attempted
to apply a quantitative visual scoring system to the hind paws of
the formalin-injected mice in an effort to determine if trilostane
demonstrates any anti-inﬂammatory properties in the formalin-
induced hyperalgesia model. Unfortunately, this effort was unsuc-
cessful because the inﬂammation was not intense enough to
generate adequate swelling to make such a scoring system
feasible. Due to the small magnitude of swelling, the pharmaco-
logic window was therefore not large enough to observe a
trilostane-mediated anti-inﬂammatory effect.
Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase,
which catalyzes the conversion of pregnenolone to progesterone
and is critically involved in the production of corticosterone
and aldosterone production in the adrenal glands.37 This
mechanism of action is not thought to play a role in inﬂammation
or analgesia, suggesting that trilostane may affect other mecha-
nisms involved in these indications. Elucidating the exact
mechanism of action of trilostane in inﬂammatory and nocicept-
ion would be difﬁcult and is beyond the scope of this brief
report.
Glucocorticoid steroids such as dexamethasone are used as a ﬁrst-
line treatment for inﬂammatory diseases. It is important to determine
whether the anti-inﬂammatory and analgesic activities of trilostane
are mediated via glucocorticoid receptors or whether these results
indicate that a novel mechanism is involved. In sheep, it is known
that trilostane increases the activity of 11β-hydroxysteroid dehydro-
genase,38 and it is not clear whether this effect or other off-target
activities in mice are responsible for our ﬁndings.
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The results of these studies suggest that trilostane has novel
anti-inﬂammatory and analgesic activities in mouse models. To
our knowledge, this effect had not been reported previously. It is
beyond the scope of this short communication to address the
mechanism behind these effects. In April 1994, trilostane was
withdrawn by the FDA from human use in the US market.
However, it is still available for human use in the United Kingdom
for the treatment of breast cancer and Cushing’s disease.39,40
Patients with postmenopausal breast cancer are usually treated
with antiestrogens and aromatase inhibitors. Unfortunately, resist-
ance to these treatments often occurs over time. Trilostane, as an
allosteric modulator of the estrogen receptor that targets both the
estrogen and growth factor–dependent pathways, offers an alter-
native approach.39 For the treatment of life-threatening diseases
such as cancer, the use of trilostane can be justiﬁed. The applica-
tion of trilostane in pain and inﬂammatory disease remains to be
seen; however, the safety proﬁle of trilostane is likely to prohibit
its long-term use in patients with these conditions. Moreover, the
effects of the current standard of care in pain and inﬂammatory
disease models are superior to trilostane, making trilostane’s long-
term use in these disease areas less desirable.
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